The Food and Drug Administration has approved the first ever pill to treat postpartum depression (PPD) which is suffered by around one in seven new mothers.
Zuranolone, which is an antidepressant, is a once-a-day pill, taken for two weeks. It will be sold under the brand name Zurzuvae.
Clinical trials showed it improved the symptoms of new mothers who were experiencing severe depression after having a baby.
The only other medication on the market for PPD, Zulresso, needs to be